EMA — authorised 20 March 2017
- Marketing authorisation holder: GlaxoSmithKline Trading Services Limited
- Status: approved
🇪🇺 Incruse Ellipta in European Union
EMA authorised Incruse Ellipta on 20 March 2017
Marketing authorisation
Incruse Ellipta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in European Union
Frequently asked questions
Is Incruse Ellipta approved in European Union?
Yes. EMA authorised it on 20 March 2017.
Who is the marketing authorisation holder for Incruse Ellipta in European Union?
GlaxoSmithKline Trading Services Limited holds the EU marketing authorisation.